Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

APRI 1.14 -0.02 (-1.72%)
price chart
Apricus Biosciences Incorporated (NASDAQ:APRI) Shorted Shares Decreased By 1.54%
The short interest to Apricus Biosciences Incorporated's float is 8.31%. The stock is up 1.72% or $0.02 after the news, hitting $1.18 per share.
Alexander J. Denner Buys 1306819 Shares of Apricus Biosciences Inc (APRI) Stock
Apricus Biosciences logo Apricus Biosciences Inc (NASDAQ:APRI) major shareholder Alexander J. Denner bought 1,306,819 shares of Apricus Biosciences stock in a transaction that occurred on Tuesday, January 12th.
Sarissa Capital Management LP Maintains Stake in Apricus Biosciences Inc (APRI)  Corvus Business Newswire
Analyst's Review on: Apricus Biosciences Inc  iStreetWire
Brokerages Set Apricus Biosciences Inc (NASDAQ:APRI) Target Price at $3.27
Apricus Biosciences logo Shares of Apricus Biosciences Inc (NASDAQ:APRI) have been assigned an average recommendation of “Hold” from the five research firms that are presently covering the company, Market Beat Ratings reports.
Apricus Biosciences Inc (APRI) Cut to Hold at Zacks Investment Research
Apricus Biosciences logo Apricus Biosciences Inc (NASDAQ:APRI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Marketbeat.
Apricus Biosciences Announces $10 Million Registered Direct Offering  GlobeNewswire (press release)
Apricus Biosciences Inc (APRI) Stake Owned by Sarissa Capital Management LP
Apricus Biosciences logo Sarissa Capital Management LP recently disclosed that they own 17.9% of Apricus Biosciences Inc (NASDAQ:APRI) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Thursday, ...
Momentum Rating Apricus Biosciences, Inc (NASDAQ:APRI)  Enterprise Leader
Alex Denner's Sarissa Capital Management Lp Just increased Apricus ...  OctaFinance.com
Apricus Biosciences Inc (NASDAQ:APRI) Expected to Post Earnings of -$0.12 Per ...
Apricus Biosciences logo Brokerages predict that Apricus Biosciences Inc (NASDAQ:APRI) will post earnings of ($0.12) per share for the current quarter, according to Zacks.
Active Stocks: BIND Therapeutics, (NASDAQ:BIND), Yirendai (NYSE:YRD ...  Benchmark Monitor
Price Target Update On Apricus Biosciences, Inc (APRI)
A number of investment brokers have recently updated their price targets on shares of Apricus Biosciences, Inc (APRI).
Top Growth Pick: Apricus Biosciences, Inc (NASDAQ:APRI)
Apricus Biosciences, Inc (NASDAQ:APRI) has received a top Growth Style score from Zack's Research. The growth score is based on company financials as well as the company's prospects for future growth.
Apricus Biosciences Inc (APRI) Major Shareholder Alexander J. Denner Buys ...
Apricus Biosciences logo Apricus Biosciences Inc (NASDAQ:APRI) major shareholder Alexander J. Denner purchased 1,306,819 shares of the firm's stock in a transaction on Tuesday, January 12th.
Apricus Biosciences Inc (APRI) Stake Held by Sarissa Capital Management LP  Zolmax
Apricus Biosciences Inc (APRI) Rating Lowered to Hold at Zacks Investment ...  Intercooler Financial
Apricus Biosciences (APRI) Lays Out 2016 Growth Strategy
“2015 was a very productive year for Apricus as we achieved our primary goals of advancing our clinical pipeline and enhancing the commercial value of Vitaros,” said Richard Pascoe, Chief Executive Officer.